Dne 29. dubna 2020 získala společnost Cytokine round A financování od VC fondu Lighthouse Seed Fund se sídlem v Lucembursku pro svůj další čtyřletý vývoj a klinické hodnocení léčiva, označeného jako „mHAM orthopedics 1102 injectable“. Jedná se o lék na bázi lidského amnionu pro léčbu symptomů osteoartrózy. Výše financování v round A nebyla stranami zveřejněna.
At 29. th of April 2020 got Cytokine round A financing from VC fund Lighthouse Seed Fund Luxemburg for another four years development and clinical testing of the „mHAM orthopedics 1102 injectable“, which is human amnion based drug candidate for Osteoarthritis symptoms treatment. The size of the investment was not disclosed.
Cytokine sro: SPV for drug candidate mHAM 1102 drug candidate, which is based on Primecell´s fifteen years experience with cell and tissue products, for example NTC Chondrograft®, which is in phase II/III clinical trial in EU, and extraordinary orthopedics outputs of University hospital Kralovske Vinohrady in Prague. Cytokine Bioscience is a spin-off Primecell´s research labs 4MEDi and NATIC, similarly as a spin-off Biohealing (2018). Research of the drug candidate was granted by Technology agency of Czech Republic. www.cytokinebio.com
Lighthouse Ventures: an early-stage and acceleration venture capital, focused on technology projects with global vision. www.lhv.vc
Primecell Bioscience: founded 2008, is a bio-med company focusing on discovering and clinical testing of biological drugs and medicinal technologies, which are changing genes and cells parameters to support regeneration of human tissues and organs. www.primecell.eu
Media contact: Elen Šťastná MD, elen.stastna@primecell.eu
